TY - JOUR
T1 - Immunotherapy in Lung Cancer
AU - Du, Lingling
AU - Herbst, Roy S.
AU - Morgensztern, Daniel
PY - 2017/2/1
Y1 - 2017/2/1
N2 - The treatment of patients with good performance status and advanced stage non–small cell lung cancer has been based on the use of first-line platinum-based doublet and second-line docetaxel. Immunotherapy represents a new therapeutic approach with the potential for prolonged benefit. Although the vaccines studied have not shown benefit in patients with non–small cell lung cancer, immune checkpoint inhibitors against the PD-1/PD-L1 axis showed increased overall survival compared with docetaxel in randomized clinical trials, which led to the approval of nivolumab and pembrolizumab. Because only a minority of patients benefit from this class of drugs, there has been an intense search for biomarkers.
AB - The treatment of patients with good performance status and advanced stage non–small cell lung cancer has been based on the use of first-line platinum-based doublet and second-line docetaxel. Immunotherapy represents a new therapeutic approach with the potential for prolonged benefit. Although the vaccines studied have not shown benefit in patients with non–small cell lung cancer, immune checkpoint inhibitors against the PD-1/PD-L1 axis showed increased overall survival compared with docetaxel in randomized clinical trials, which led to the approval of nivolumab and pembrolizumab. Because only a minority of patients benefit from this class of drugs, there has been an intense search for biomarkers.
KW - Immune checkpoint inhibitors
KW - Non–small cell lung cancer
KW - PD-L1
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=84998910081&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2016.08.004
DO - 10.1016/j.hoc.2016.08.004
M3 - Review article
C2 - 27912829
AN - SCOPUS:84998910081
SN - 0889-8588
VL - 31
SP - 131
EP - 141
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -